Zacks Research Lowers Earnings Estimates for Avanos Medical

Avanos Medical, Inc. (NYSE:AVNS) – Investment analysts at Zacks Research reduced their Q3 2025 earnings estimates for shares of Avanos Medical in a research report issued to clients and investors on Wednesday, March 19th. Zacks Research analyst R. Department now expects that the company will post earnings of $0.30 per share for the quarter, down from their prior estimate of $0.43. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical’s FY2025 earnings at $1.20 EPS, Q2 2026 earnings at $0.30 EPS and FY2026 earnings at $1.48 EPS.

Separately, StockNews.com raised shares of Avanos Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, March 19th.

Avanos Medical Price Performance

Avanos Medical stock opened at $14.67 on Monday. The company’s 50 day simple moving average is $15.83 and its 200-day simple moving average is $18.65. The company has a market capitalization of $675.05 million, a price-to-earnings ratio of 43.16 and a beta of 1.17. Avanos Medical has a 1 year low of $14.25 and a 1 year high of $25.36. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22.

Avanos Medical (NYSE:AVNS) last released its quarterly earnings results on Wednesday, February 26th. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.40 by $0.03. The business had revenue of $179.60 million for the quarter, compared to the consensus estimate of $177.23 million. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in AVNS. T. Rowe Price Investment Management Inc. grew its holdings in Avanos Medical by 27.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,011,312 shares of the company’s stock worth $47,941,000 after acquiring an additional 644,267 shares in the last quarter. Tributary Capital Management LLC grew its holdings in Avanos Medical by 38.1% during the 4th quarter. Tributary Capital Management LLC now owns 893,008 shares of the company’s stock worth $14,217,000 after acquiring an additional 246,379 shares in the last quarter. Brown Advisory Inc. grew its holdings in Avanos Medical by 12.0% during the 4th quarter. Brown Advisory Inc. now owns 1,905,094 shares of the company’s stock worth $30,329,000 after acquiring an additional 204,218 shares in the last quarter. D. E. Shaw & Co. Inc. grew its holdings in Avanos Medical by 43.1% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 494,627 shares of the company’s stock worth $7,874,000 after acquiring an additional 148,902 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Avanos Medical by 189.8% during the 4th quarter. JPMorgan Chase & Co. now owns 201,634 shares of the company’s stock worth $3,210,000 after acquiring an additional 132,063 shares in the last quarter. Institutional investors and hedge funds own 95.17% of the company’s stock.

Insider Buying and Selling

In related news, SVP Kerr Holbrook sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $15.25, for a total transaction of $106,750.00. Following the sale, the senior vice president now directly owns 82,047 shares of the company’s stock, valued at $1,251,216.75. This represents a 7.86 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.94% of the stock is owned by insiders.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.